ReviewMolecular imaging
Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy.
Review in Molecular imaging. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 60 citations in OpenAlex.
- Bibliometric analysis of programmed death ligand-1 positron emission tomography probe research: development, landscape, and technological evolution.Nuclear medicine communications · 2026Article
- Noninvasive ImmunoPET imaging of PD-L1 expression in non-small cell lung cancer and bladder cancer using [Colloids and surfaces. A, Physicochemical and engineering aspects · 2025Article
- Article
- Synthesis and Evaluation of [Pharmaceutics · 2025Article
- Synthesis and In Vitro Evaluation of a Scandium-44 Radiolabeled Nanobody as a PD-L1 PET Imaging Probe.Pharmaceutics · 2025Article
- A PD-L1-Targeted Probe Cy5.5-A11 forACS omega · 2024Article
- Synthesis and evaluation of anti-PD-L1-B11 antibody fragments for PET imaging of PD-L1 in breast cancer and melanoma tumor models.Scientific reports · 2024Article
- Specific Cell Targeting byCells · 2024Article
- ImmunoPET provides a novel way to visualize the CD103EJNMMI research · 2024Review
- Cancer Immunotherapy and Medical Imaging Research Trends from 2003 to 2023: A Bibliometric Analysis.Journal of multidisciplinary healthcare · 2024Review
- Tracking tumor heterogeneity and progression with near-infrared II fluorophores.Exploration (Beijing, China) · 2023Review
- Present status and future trends in molecular imaging of lymphocytes.Seminars in nuclear medicine · 2023Review
- Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display.ACS chemical biology · 2022Article
- Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Imaging immunity in patients with cancer using positron emission tomography.NPJ precision oncology · 2022Review
- Molecular Immune Targeted Imaging of Tumor Microenvironment.Nanotheranostics · 2022Review
- Noninvasive Imaging of Cancer Immunotherapy.Nanotheranostics · 2021Review
- Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges.Cancers · 2020Review
- Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Immunotherapy holds great promise in cancer treatment. The challenges in advancing immunotherapies lie in patient stratification and monitoring therapy. Noninvasive detection of immune checkpoint ligand PD-L1 can serve as an important biomarker for guidance and monitoring of immunotherapy. Here in, we provide an overview of our efforts to develop clinically translatable PD-L1-specific imaging agents for quantitative and real-time assessment of PD-L1 expression in tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.